Sanofi (NASDAQ:SNY) Sets New 52-Week Low – Here’s What Happened

Sanofi (NASDAQ:SNY)’s stock price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $43.15 and last traded at $43.35, with a volume of 2895548 shares. The stock had previously closed at $46.08.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on SNY shares. Morgan Stanley set a $52.00 price objective on Sanofi in a research note on Friday, May 1st. Argus raised Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Weiss Ratings downgraded Sanofi from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 29th. Finally, Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Sanofi currently has a consensus rating of “Hold” and a consensus target price of $51.00.

Sanofi Trading Up 0.9%

The stock has a market cap of $106.76 billion, a P/E ratio of 12.23, a P/E/G ratio of 1.07 and a beta of 0.35. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The company has a 50-day moving average price of $46.25 and a two-hundred day moving average price of $47.81.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be given a dividend of $2.4225 per share. The ex-dividend date of this dividend is Monday, May 4th. This represents a dividend yield of 559.0%. This is an increase from Sanofi’s previous annual dividend of $2.04. Sanofi’s dividend payout ratio is presently 49.44%.

Hedge Funds Weigh In On Sanofi

Several hedge funds have recently bought and sold shares of the business. Advisory Services Network LLC grew its position in Sanofi by 1.4% in the 3rd quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock valued at $743,000 after acquiring an additional 210 shares during the last quarter. Waterfront Wealth Inc. grew its position in Sanofi by 0.4% in the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock valued at $2,463,000 after acquiring an additional 214 shares during the last quarter. Savant Capital LLC grew its position in Sanofi by 2.7% in the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock valued at $418,000 after acquiring an additional 225 shares during the last quarter. HighPoint Advisor Group LLC grew its position in Sanofi by 2.3% in the 3rd quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock valued at $468,000 after acquiring an additional 226 shares during the last quarter. Finally, Wesbanco Bank Inc. grew its position in Sanofi by 4.9% in the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock valued at $239,000 after acquiring an additional 230 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.